TITLE

THROMBOLYTIC ACTIVITY OF CENTELLA ASIATICA LEAVES

AUTHOR(S)
Rishikesh; Ghosh, Drishti Rani; Rahman, Moshfiqur
PUB. DATE
April 2013
SOURCE
International Journal of Pharmacy;2013, Vol. 3 Issue 2, p308
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The methanol extract of Centella asiatica was estimated for thrombolytic effect. The extract demonstrated moderate thrombolytic activity which was 25.01 % where as the thrombolytic activity of standard was found 88.23 %. Thrombolytic indicates that have potent clot lysis property and anti-oxidative activity. The result showed momentous effect with comparison to standard thrombolytic agent, streptokinase. The obtained results support for the uses of this plant as traditional medicine.
ACCESSION #
87012500

 

Related Articles

  • Thrombolytic Agents: The Science of the Art of Choosing the Better Treatment. Farkouh, Michael E.; Lang, Jeff D.; Sackett, David L. // Annals of Internal Medicine;5/15/94, Vol. 120 Issue 10, p886 

    Editorial. Discusses whether the thrombolytic agent of choice for patients with suspected heart attacks should be tissue plasminogen activator or streptokinase. Mechanism of action of the agents; Elements of the science of making clinical judgments.

  • Fibrin Binding and the Regulation of Plasminogen Activators during Thrombolytic Therapy. Longstaff, C.; Williams, S.; Thelwell, C. // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 3, p212 

    First generation thrombolytics (streptokinase and urokinase) had no fibrin binding capabilities and caused systemic plasminogen activation with concomitant destruction of haemostatic proteins. A primary driving force behind the development of the second generation plasminogen activator tissue...

  • Production and partial purification of streptokinase from Streptococcus pyogenes. Felsia, X. Freeda; Vijayakumar, R.; Kalpana, S. // Journal of Biochemical Technology;2011, Vol. 3 Issue 2, p1 

    Streptokinase is as effective as recombinant tissue plasminogen activator (tPA) in treating acute myocardial infarction and it is certainly more cost-effective. In view of the relatively recent availability of the competing recombinant tPA, skepticism is being expressed about the continued...

  • Spotlight on Reteplase in Thrombotic Occlusive Disorders. Simpson, Dene; Siddiqui, M. Asif A.; Scott, Lesley J.; Hilleman, Daniel E. // BioDrugs;2007, Vol. 21 Issue 1, p65 

    Reteplase (Retavase) is a plasminogen activator, mimicking endogenous tissue plasminogen activator (t-PA), a serine protease, converting plasminogen to plasmin and thereby precipitating thrombolysis. It is a third-generation recombinant form of t-PA that operates in the presence of fibrin (i.e....

  • Systemic Thrombolysis Using Tissue Plasminogen Activator for a Patient With Paradoxic Embolism: A Case Report. Zhen Fan; Roedersheimer, Richard; Lohr, Joann // Vascular & Endovascular Surgery;Apr/May2007, Vol. 41 Issue 2, p136 

    When thrombotic material that originates from deep venous thrombosis of the lower extremities is washed out into the pulmonary vasculature, pulmonary embolization occurs. Pulmonary embolism and associated acute peripheral ischemia suggest the diagnosis of paradoxic embolism, which is most often...

  • Cardiovascular Disease. Gore, Joel M.; Dalen, James E. // JAMA: Journal of the American Medical Association;6/19/91, Vol. 265 Issue 23, p3105 

    Reports on some developments in the treatment of cardiovascular disease as of June 1991. Thrombolytic therapy; Risks and benefits of tissue plasminogen activator (TPA) and streptokinase; Importance of heparin therapy in patients treated with TPA.

  • T-PA beats streptokinase in latest battle. Hurley, Mary Lou // RN;Sep93, Vol. 56 Issue 9, p92 

    Reports on the effectivity of tissue plasminogen activator altephase (Activase) in treating patients after a myocardial infarction than treatment with streptokinase (Kabikinase, Streptase). Results of study conducted on patients given the drugs; Mortality rate after 30 days; Incidence of stroke.

  • Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger. Adatia, Sweta; Sanghani, Sejal; Sanzgiri, Prakash; Chauhan, Vinay; Hastak, Shirish // Annals of Indian Academy of Neurology;Jan-Mar2010, Vol. 13 Issue 1, p64 

    Thrombolysis with intravenous tissue (IV) plasminogen activator (tPA) is considered for patients with acute ischemic stroke falling within the described inclusion criteria defined by The National Institute of Neurological Disorders and Stroke (NINDS) rtPA trial. Complications of IV thrombolysis...

  • Thrombolytic Therapy in Acute Stroke: Outcome, Barriers & How to Overcome. AHASAN, HAM NAZMUL; HOSSAIN, YEANUR; DAS, APARNA; MINNAT, BAHARUL; CHOWDHURY, MOSTOFA KAMAL // Journal of Medicine;2013, Vol. 14 Issue 1, p65 

    The article discusses aspects on the use of thrombolytic therapy in treating acute stroke and examines the outcome and barriers of the treatment. Topics discussed include the mortality and prevalence of stroke, the use of recombinant tissue plasminogen activator (rt-PA), and the clinical use of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics